Alpa Laboratorie Share Price ₹59.6 | P/E 32.0

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Financials of Alpa Laboratorie

Quarter-by-quarter operating performance

	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Sales +	27.31	29.16	25.43	32.39	27.31	23.61	21.44	24.94	26.15	39.92	19.11	26.26	29.05
Expenses +	24.69	19.94	26.57	29.04	24.88	20.10	20.91	21.62	25.41	39.72	18.68	28.51	27.54
Operating Profit	2.62	9.22	-1.14	3.35	2.43	3.51	0.53	3.32	0.74	0.20	0.43	-2.25	1.51
OPM %	9.59%	31.62%	-4.48%	10.34%	8.90%	14.87%	2.47%	13.31%	2.83%	0.50%	2.25%	-8.57%	5.20%
Other Income +	2.67	-0.69	4.47	2.95	3.55	3.98	5.16	6.91	8.80	2.48	11.94	3.06	0.91
Interest	0.07	0.04	0.02	0.02	0.02	0.29	0.05	0.05	0.09	0.02	0.05	0.03	0.03
Depreciation	0.10	0.53	0.28	0.49	0.66	0.52	0.54	0.53	0.55	0.58	0.55	0.67	0.65
Profit before tax	5.12	7.96	3.03	5.79	5.30	6.68	5.10	9.65	8.90	2.08	11.77	0.11	1.74
Tax %	0.00%	41.58%	0.00%	0.00%	14.91%	46.71%	0.00%	20.31%	0.00%	201.92%	0.00%	0.00%	-9.20%
Net Profit +	5.12	4.65	3.03	5.79	4.51	3.55	5.10	7.69	8.90	-2.12	11.77	0.11	1.90
EPS in Rs	2.43	2.21	1.44	2.75	2.14	1.69	2.42	3.65	4.23	-1.01	5.59	0.05	0.90

Financials of Alpa Laboratorie

Annual income statement trend

	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales +	56	57	53	63	62	77	85	97	112	93	109	110	114
Expenses +	51	54	47	56	58	76	80	90	101	85	100	105	114
Operating Profit	6	3	7	7	4	1	6	8	11	8	9	5	-0
OPM %	10%	6%	13%	11%	7%	1%	7%	8%	10%	9%	8%	4%	-0%
Other Income +	1	2	5	3	5	5	0	4	11	9	14	23	18
Interest	2	2	1	2	1	1	0	0	0	0	0	0	0
Depreciation	9	6	1	3	3	3	3	1	2	1	2	2	2
Profit before tax	-5	-3	10	6	5	3	3	11	20	16	21	26	16
Tax %	4%	-48%	30%	55%	39%	63%	36%	33%	28%	21%	19%	24%
Net Profit +	-5	-1	7	3	3	1	2	7	14	13	17	20	12
EPS in Rs	-2.45	-0.67	3.26	1.20	1.34	0.48	0.88	3.45	6.70	5.98	7.98	9.27	5.53
Dividend Payout %	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

Financials of Alpa Laboratorie

Capital structure and asset base

	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Sep 2025
Equity Capital	21	21	21	21	21	21	21	21	21	21	21	21	21
Reserves	67	66	72	74	77	77	79	87	101	114	131	150	162
Borrowings +	23	29	24	11	6	2	0	0	6	2	5	0	0
Other Liabilities +	15	13	27	20	18	21	21	33	28	30	25	51	54
Total Liabilities	127	128	144	126	122	121	121	140	155	167	182	223	238
Fixed Assets +	73	5	15	15	10	8	6	7	9	7	11	21	21
CWIP	0	0	0	0	0	0	1	2	0	0	0	0	0
Investments	0	10	12	13	31	49	57	51	75	78	98	118	145
Other Assets +	54	113	118	97	81	65	58	81	71	82	73	84	71
Total Assets	127	128	144	126	122	121	121	140	155	167	182	223	238

Financials of Alpa Laboratorie

Operating, investing and financing cash movement

	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operating Activity +	8	-2	-22	17	-13	-1	18	-2	10	9	4	18
Cash from Investing Activity +	-2	37	-8	-2	-11	-15	-11	6	-16	2	-13	-12
Cash from Financing Activity +	4	7	-6	-15	9	-5	-1	0	5	-4	3	-5
Net Cash Flow	10	42	-36	0	-15	-20	5	4	-0	7	-7	1
Free Cash Flow	6	-3	-32	16	-15	-2	15	-5	8	8	-3	7
CFO/OP	146%	-92%	-277%	283%	-263%	102%	324%	15%	123%	155%	85%	466%

Financials of Alpa Laboratorie

Working capital efficiency and return ratios

	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Debtor Days	130	156	234	168	153	142	105	133	124	184	138	155
Inventory Days	148	76	196	131	138	105	90	102	81	84	73	92
Days Payable	121	91	244	140	134	99	98	152	78	100	63	97
Cash Conversion Cycle	157	141	187	159	157	149	97	83	127	168	149	150
Working Capital Days	65	-5	204	174	208	194	125	140	118	152	135	110
ROCE %		0%	10%	8%	6%	3%	5%	7%	9%	12%	15%	16%

Novartis India Ltd (Q1 FY27)
Focused growth in six core therapy areas: cardiology, pain management, women's health, CNS, transplant, and ophthalmology, which contribute 40-50% of…
IOL Chemicals & Pharmaceuticals Ltd (Q1 FY27)
Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…
Innova Captab Ltd (Q1 FY27)
The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…
Glenmark Pharmaceuticals Ltd (Q1 FY27)
Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…

Alpa Laboratorie Share Price & Earnings Call Analysis